6th Obesity and NASH Drug Development Summit 2022

Kongressthemen
The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
Brochure: https://go.evvnt.com/1277295-3?pid=4832

Speakers: Allison Goldfine, Director, Translational Medicine Cardiometabolic Disease, Novartis, Andrew Billin, Senior Director Biomarker Sciences, Gilead, and more.

https://go.evvnt.com/1277295-2?pid=4832

Frau Jessica Durston